Agregación de proteínas: estrategias terapéuticas, diagnóstico y aplicaciones

Keyphrases

1. Amyloid Fibrils 100%
2. Nanostructures 100%
3. Protein Aggregation 68%
4. Amyloidogenicity 68%
5. Amyloid-like 66%
6. Plasmonic Biosensor 57%
7. Inhibitor Synthesis 57%
8. Antibody Conjugates 57%
9. Intrinsically Disordered Proteins 57%
10. Peptide-based 57%
11. Cell-cell Interaction 57%
12. Phase Separation 57%
13. Inhibitor Evaluation 57%
14. Multispecific Antibodies 57%
15. Alpha-synuclein (α-syn) 57%
16. Specific Cell Targeting 57%
17. Amyloidogenic Regions 57%
18. PH Dependence 57%
19. Biosensor Applications 57%
20. Amyloidogenesis Inhibitors 57%
21. Disease-causing mutations 57%
22. Transthyretin 57%
23. Helical Peptides 57%
24. Targeted Delivery 57%
25. Nanorods 57%
26. Oligomeric Nanoparticles 57%
27. Drug Delivery 57%
28. Functional Oligomers 57%
29. Plasmodium Parasite 57%
30. Alternative Splicing 57%
31. Prion 57%
32. Blood Stage 57%
33. Inhibitor Design 57%
34. Heterogeneous Ribonucleoproteins 57%
35. Specific Detectivity 57%
36. Toxic Oligomers 57%
37. Nanomaterials 47%
38. Functional Amyloid 42%
39. Plasmodium Falciparum 38%
40. Streptavidin 38%
41. Horseradish Peroxidase 38%
42. Malaria Parasite 38%
43. Prion-like 34%
44. Functional Nanomaterials 33%
45. Globular Domain 33%
46. Polypeptide 30%
47. Aggregation Propensity 30%
48. Protein Fusion 28%
49. Biocompatibility 28%
50. Modular Design 28%
51. Protein-based 28%
52. Natural Selection 28%
53. Enzymatic Assay 28%
54. Tight Control 28%
55. Novel Protein 28%
56. Biological Activity 28%
57. Bioimaging 28%
58. Protein Assembly 28%
59. Biocatalysis 28%
60. Highly Active 28%
61. Methotrexate 28%
62. Bottom-up Strategy 28%
63. Yeast Prion 28%
64. Antibody Binding 28%
65. Methylenetetrahydrofolate Reductase (MTHFR) 28%
66. Flexible Linker 28%
67. Multi-target 28%
68. Multifunctional Nanoparticles 28%
69. Cancer Cells 28%
70. Z-domain 28%
71. Targeted Therapy 28%
72. Supramolecular Structure 28%
73. Embedded Enzyme 28%
74. Biophysical Assays 28%
75. Localized Delivery 28%
76. Intracellular Uptake 28%
77. Mesoscopic Properties 28%
78. Amyloid Deposition 27%
79. Multivalent 25%
80. Protein Solubility 22%
81. Parkinson's Disease 22%
82. RNA Processing 22%
83. High Affinity 19%
84. Electron Microscopy Images 19%
85. Phosphatase Activity 19%
86. Oligomerization 19%
87. Quantum Dots 19%
88. Rapid Evolution 19%
89. Aggregated Protein 19%
90. Aggregation-prone Peptides 19%
91. Amyloid Nanofibers 19%
92. Natural Proteins 19%
93. Post-assembly 19%
94. Multivalent Approach 19%
95. Biocompatible Platforms 19%
96. Typical Building 19%
97. Linker 19%
98. Glucose Oxidase-peroxidase 19%
99. Steric Repulsion 19%
100. Living Cells 19%
101. Heptapeptide 19%
102. Intracellular Amyloid 19%
103. Culture in Vitro 19%
104. Biotin 19%
105. Plasmodium Berghei 19%
106. New Therapeutic Approaches 19%
107. Peroxidase-like Activity 19%
108. Proteomic Approach 19%
109. Proteostasis 19%
110. Aggregation-prone Protein 19%
111. Single Cell Protein 19%
112. Dynamic Bodies 19%
113. Glucose Biosensor 19%
114. Aggregation-prone 19%
115. Resistance Evolution 19%
116. High Protein 19%
117. Female Gamete 19%
118. Blockage 19%
119. Biotin-streptavidin System 19%
120. Fluorescence Measurement 19%
121. Protein Complex 19%
122. Transmission Electron Microscope 19%
123. On Demand 19%
124. Modular Approach 19%
125. Gold Nanoparticles 19%
126. Protein Engineering 19%
127. Protein Amyloids 19%
128. Linker Length 19%
129. Functional Domain 19%
130. Soluble Nanoparticles 19%
131. Alkaline Phosphatase 19%
132. Number of Strands 19%
133. Protein Aggregates 19%
134. Cross-core 19%
135. Cross Structure 19%
136. Targeted Molecular Dynamics 19%
137. Short Peptides 19%
138. Amorphous Aggregates 19%
139. Molecular Targets 19%
140. Rigid Body Simulation 19%
141. Globular Structure 19%
142. Multiple Genes 19%
143. Thioflavin T 19%
144. Nanoparticles 19%
145. Self-assembly 19%
146. Gene Products 19%
147. Biological Processes 19%
148. Plasmodium Yoelii 19%
149. Intraerythrocytic Development Cycle 19%
150. Upsetting 19%
151. Mosquito Stages 19%
152. Nuclear Import 19%
153. Functional Role 19%
154. Murine Malaria 19%
155. Molecular Dynamics Simulation 16%
156. Conjugation 14%
157. Target Receptor 14%
158. Antibody Capture 14%
159. Antibody Binding Capacity 14%
160. Modular Methodology 14%
161. Tumoral Cells 14%
162. Antibody Binding Affinity 14%
163. Pathogenic Cells 14%
164. Bispecific Antibody 14%
165. Biomolecules 14%
166. Antibody-mediated 14%
167. Covalent Modification 14%
168. Nanostructured Surfaces 14%
169. Nanofibrils 14%
170. High Biocompatibility 14%
171. T Cells 14%
172. Therapeutic Use 14%
173. Diagnostic Applications 14%
174. Molecular Entity 14%
175. Specific Antibodies 14%
176. Multivalent Antibody 14%
177. Plasmonic Platforms 11%
178. Point-of-care Measurements 11%
179. Affinity Binder 11%
180. Disordered Regions 11%
181. Splice Isoforms 11%
182. Nuclear Complex 11%
183. Parkinson's Disease Diagnosis 11%
184. Excellent Selectivity 11%
185. Protein Aggregation Propensity 11%
186. Direct Detection 11%
187. Solvent Conditions 11%
188. Cerebrospinal Fluid 11%
189. Early Diagnosis 11%
190. Phase Separate 11%
191. Functional Mechanism 11%
192. Neurodegenerative Diseases 11%
193. Muscular Diseases 11%
194. Lipophilicity 11%
195. Phenomenological Models 11%
196. Changing Environmental Conditions 11%
197. On-a-chip 11%
198. Plasmonics 11%
199. Drosophilidae 11%
200. Dedicated Software 11%